UroLume endoprosthesis linked to high restenosis and explantation rates in urethral stricture and BPHUroLume stent tied to high rates of tissue regrowth

World journal of urology Published August 5, 2026 Study authors: Kapos Ioannis P PubMed ↗ DOI ↗ Editorial oversight: Dr. Lars van Dijk, PhD · Surgical, Procedural & Diagnostic

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider UroLume endoprosthesis as a high-risk option; monitor closely for restenosis, explantation, and incontinence.

This systematic review and meta-analysis synthesizes data from 3847 patients who received a UroLume endoprosthesis for bulbar urethral stricture or benign prostatic hyperplasia. The quantitative pool included 2730 patients, all with a minimum follow-up of 12 months. The primary endpoints were restenosis/tissue ingrowth, stent explantation, and urinary incontinence.

Pooled rates were 37.9% (95% CI 36.1-39.8%, I²=0%) for restenosis/tissue ingrowth, 8.7% (95% CI 7.7-9.8%, I²=0%) for stent explantation, and 9.7% (95% CI 8.7-10.9%, I²=0%) for urinary incontinence. Complete epithelialisation was irreversible after 12 months in approximately 8-13% of cases.

The authors introduce a conceptual framework termed "UroLume Cripple Syndrome" to describe the complex iatrogenic condition that can arise after implantation. They also note potential long-term complications including irreversible urethral destruction, spongiofibrosis, multidrug-resistant infections, and chronic kidney disease.

Limitations include the hypothesis-generating nature of the epidemiological model, which was based on fewer than 100 patients. The authors emphasize the need for structured registry creation and guideline consensus to better manage this condition.

For clinicians, these findings highlight the substantial complication burden associated with UroLume endoprosthesis and support careful patient selection and long-term surveillance.

How this fits prior evidence

This meta-analysis extends prior coverage on BPH interventions by quantifying the long-term complications of a specific device, the UroLume endoprosthesis. It contrasts with the favorable outcomes reported for ThuLEP versus RASP in large-volume BPH, underscoring that device choice carries distinct trade-offs. It also complements the finding that curcumin improves IPSS scores, as both address BPH management but via different mechanisms. The high restenosis and explantation rates reinforce the need for careful consideration of invasive options, aligning with prior cautions about adjunctive roles for IPP and the importance of weighing adverse effects.

If you or someone you know has a UroLume stent for a narrowed urethra, new research suggests a significant chance of complications. The UroLume is a small metal tube placed to keep the urethra open, often for men with strictures or an enlarged prostate. But a new meta-analysis, which combines results from many studies, found that nearly 38% of patients experienced restenosis, meaning the tissue grew back and narrowed the passage again.

The analysis looked at data from 3,847 patients who had the stent implanted, with at least 12 months of follow-up. Besides tissue regrowth, about 9% needed the stent removed, and another 9% reported urinary incontinence. The researchers also noted that in about 8 to 13% of cases, the tissue never fully healed, which could lead to permanent damage.

These numbers are sobering, but the study has limitations. The researchers call their model "hypothesis-generating," meaning it points to possible risks but doesn't prove cause and effect. They also identified a condition they call "UroLume Cripple Syndrome," but that's a concept, not a confirmed diagnosis.

If you have a UroLume stent or are considering one, talk to your doctor about these risks. This isn't medical advice, but it's information worth bringing up in your next appointment.

What this means for you:

UroLume stents carry a high risk of tissue regrowth and other complications, so discuss alternatives with your doctor.

Common questions

What is a UroLume stent?

A UroLume stent is a small metal tube placed in the urethra to keep it open. It's used for men with narrowing from strictures or an enlarged prostate. The stent is meant to be a permanent solution, but this study shows it often leads to complications.

What are the main complications of UroLume stents?

The most common complication is tissue regrowth (restenosis), which happened in about 38% of patients. About 9% needed the stent removed, and another 9% had urinary incontinence. Some patients also experienced permanent urethral damage or infections.

How long do complications take to appear?

This study followed patients for at least 12 months. Tissue regrowth and other issues can show up within that first year, but some problems, like incomplete healing, may become irreversible after 12 months. Long-term risks beyond that aren't fully known.

Should I have my UroLume stent removed?

This study doesn't say whether removal is right for you. It only reports that about 9% of patients needed explantation due to complications. If you're concerned, talk to your urologist about your specific situation and options.

Study Details

Study typeMeta analysis

Sample sizen = 3,847

EvidenceLevel 1

Follow-up12.0 mo

PublishedAug 2026

PMID42552506

View Original Abstract ↓

BACKGROUND: The UroLume endoprosthesis (AMS/Endo-care), commercially available 1988-2007 and FDA-approved in 1996, was positioned as a permanent minimally invasive solution for recurrent bulbar urethral stricture and benign prostatic hyperplasia. Despite early procedural success, long-term data revealed a severe complication profile-including irreversible urethral destruction, spongiofibrosis, MDR infections, chronic kidney disease, and significant psychological morbidity-culminating in a clinical entity described here under an author-proposed conceptual framework termed 'UroLume Cripple Syndrome'. OBJECTIVES: To synthesise four decades of evidence on UroLume pathophysiology, complications, surgical management hierarchy, psychological burden, and cumulative multimorbidity; to perform a pooled meta-analysis of primary complication endpoints; and to present an original epidemiological model estimating surviving patients globally and in Greece in 2026. METHODS: PRISMA 2020-compliant systematic review and meta-analysis. Databases searched: PubMed, Embase, Cochrane Library (inception to March 2026). INCLUSION: peer-reviewed studies of UroLume implantation, explantation, or post-UroLume reconstruction; minimum 12-month follow-up; series n ≥ 10. Study quality assessed using the Newcastle-Ottawa Scale (NOS). Random-effects meta-analysis (DerSimonian-Laird estimator) performed for three primary complication endpoints across all 43 included studies. PROSPERO registration submitted; number pending. RESULTS: Forty-three studies met inclusion criteria (n = 3847 patients). Pooled meta-analysis (n = 2730 in quantitative pool): restenosis/tissue ingrowth 37.9% (95% CI 36.1-39.8%, I = 0%); stent explantation 8.7% (95% CI 7.7-9.8%, I = 0%); urinary incontinence 9.7% (95% CI 8.7-10.9%, I = 0%). Complete epithelialisation, irreversible after 12 months, affects approximately 8-13% of long-term survivors. A six-filter epidemiological model provides a hypothesis-generating estimate of fewer than 100 clinically active patients globally exhibiting this severe profile. CONCLUSIONS: The proposed framework of UroLume Cripple Syndrome conceptualizes a complex iatrogenic condition with distinct pathophysiological, reconstructive, and psychological dimensions. Specialized published institutional pathways remain confined to fewer than 10 centers worldwide, highlighting the need for structured registry creation and guideline consensus to support this legacy cohort.

UroLume endoprosthesis linked to high restenosis and explantation rates in urethral stricture and BPHUroLume stent tied to high rates of tissue regrowth

How this fits prior evidence

Common questions

Study Details

Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC

Combination therapy shows mixed results for advanced prostate cancer

Clinical research that matters. Delivered to your inbox.

UroLume endoprosthesis linked to high restenosis and explantation rates in urethral stricture and BPHUroLume stent tied to high rates of tissue regrowth

How this fits prior evidence

Common questions

More on Benign Prostatic Hyperplasia

Study Details

Combination of PD-1/PD-L1 inhibitors and chemotherapy shows no overall survival benefit in mCRPC

Combination therapy shows mixed results for advanced prostate cancer

Clinical research that matters. Delivered to your inbox.

Related in Urology

From Other Specialties